DiaMedica Therapeutics Inc (CVE:DMA) – Equities research analysts at Zacks Investment Research issued their FY2022 earnings per share estimates for DiaMedica Therapeutics in a research note issued on Wednesday. Zacks Investment Research analyst G. Zeng forecasts that the company will post earnings of $0.24 per share for the year.
DiaMedica Therapeutics (CVE DMA) opened at C$0.42 on Friday. DiaMedica Therapeutics has a 52 week low of C$0.21 and a 52 week high of C$0.46. The stock has a market capitalization of $48.84, a PE ratio of -10.50 and a beta of 0.61.
COPYRIGHT VIOLATION NOTICE: This report was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3297872/zacks-investment-research-comments-on-diamedica-therapeutics-incs-fy2022-earnings-dma.html.
DiaMedica Therapeutics Inc is a Canada-based clinical-stage biopharmaceutical company, which focuses on recombinant proteins and monoclonal antibodies. The Company focuses on the discovery and development of treatments for stroke and other vascular diseases. It operates through segment, which is discovery and development of recombinant proteins and monoclonal antibody technology applications to treat large unmet diseases, including acute vascular disease of the brain, kidneys and heart.
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.